[18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study
European Journal of Nuclear Medicine and Molecular Imaging · 2023
DOI: 10.1007/s00259-023-06301-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Daniela-Elena Oprea-Lager und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan…. Hauptthemen laut MEDLINE: Boidae, Prostatic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Curium.
Abstract (Originalsprache)
Purpose
Primary objective was to compare the per-patient detection rates (DR) of [ 18 F]DCFPyL versus [ 18 F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR). Secondary endpoints included safety and impact on patient management (PM).
Methods
This was a prospective, open label, cross-over, comparative study with randomized treatment administration of [ 18 F]DCFPyL (investigational medicinal product) or [ 18 F]fluoromethylcholine (comparator). Men with rising prostate-specific antigen (PSA) after initial curative therapy were enrolled. [ 18 F]DCFPyL and [ 18 F]fluoromethylcholine PET/CTs were performed within a maximum time interval of 12 days. DR was defined as the percentage of positive PET/CT scans identified by 3 central imaging readers. PM was assessed by comparing the proposed pre-PET/CT treatment with the local treatment", defined after considering both PET/CTs.
Results
A total of 205 patients with first BCR after radical prostatectomy (73%; median PSA = 0.46 ng/ml [CI 0.16;27.0]) or radiation therapy (27%; median PSA = 4.23 ng/ml [CI 1.4;98.6]) underwent [ 18 F]DCFPyL- and/or [ 18 F]fluoromethylcholine -PET/CTs, between July and December 2020, at 22 European sites. 201 patients completed the study. The per-patient DR was significantly higher for [ 18 F]DCFPyL- compared to [ 18 F]fluoromethylcholine -PET/CTs (58% (117/201 patients) vs. 40% (81/201 patients), p < 0.0001). DR increased with higher PSA values for both tracers (PSA ≤ 0.5 ng/ml: 26/74 (35%) vs. 22/74 (30%); PSA 0.5 to ≤ 1.0 ng/ml: 17/31 (55%) vs. 10/31 (32%); PSA 1.01 to < 2.0 ng/ml: 13/19 (68%) vs. 6/19 (32%);PSA > 2.0: 50/57 (88%) vs. 39/57 (68%) for [ 18 F]DCFPyL- and [ 18 F]fluoromethylcholine -PET/CT, respectively). [ 18 F]DCFPyL PET/CT had an impact on PM in 44% (90/204) of patients versus 29% (58/202) for [ 18 F]fluoromethylcholine. Overall, no drug-related nor serious adverse events were observed.
Conclusions
The primary endpoint of this study was achieved, confirming a significantly higher detection rate for [ 18 F]DCFPyL compared to [ 18 F]fluoromethylcholine, in men with first BCR of PCa, across a wide PSA range. [ 18 F]DCFPyL was safe and well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. d.oprea-lager@amsterdamumc…
- Service de Médecine Nucléaire, Centre de Cancérologie de La Sarthe, Le Mans, France.
- Servicio de Medicina Nuclear, Grupo HM Hospitales, Universidad CEU San Pablo, Madrid, Spain.
- Service de Médecine Nucléaire, Hôpital Tenon, Paris, France.
- Service de Médecine Nucléaire, CHRU, Nancy, France.
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
ORCID-Profile: Daniela-Elena Oprea-Lager
Förderung
- Curium
Zitieren
APA
Oprea-Lager, D. E., Gontier, E., García-Cañamaque, L., Gauthé, M., Olivier, P., Mitjavila, M., Tamayo, P., Robin, P., García Vicente, A. M., Bouyeure, A. C., Bailliez, A., Rodríguez-Fernández, A., Mahmoud, S. B., Vallejo-Casas, J. A., Maksud, P., Merlin, C., Blanc-Durand, P., Drouet, C., Tissot, H., …, & Rousseau, C. (2023). [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06301-5
Vancouver
Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, et al. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06301-5
BibTeX
@article{OpreaLager2023,
author = {Oprea-Lager, Daniela-Elena and Gontier, Eric and García-Cañamaque, Lina and Gauthé, Mathieu and Olivier, Pierre and Mitjavila, Mercedes and Tamayo, Pilar and Robin, Philippe and García Vicente, Ana Maria and Bouyeure, Anne-Charlotte and Bailliez, Alban and Rodríguez-Fernández, Antonio and Mahmoud, Sinan Ben and Vallejo-Casas, Juan Antonio and Maksud, Philippe and Merlin, Charles and Blanc-Durand, Paul and Drouet, Clément and Tissot, Hubert and Vierasu, Irina and Vander Borght, Thierry and Boos, Evelyne and Chossat, Florence and Hodolic, Marina and Rousseau, Caroline},
title = {[18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
doi = {10.1007/s00259-023-06301-5}
}
EUVIMED